Renascience Inc. AI Stock Analysis
Want to see JP:4889 full AI Analyst Report?
Renascience Inc. (4889) AI Stock Analysis
Renascience Inc.
(TSE/TYO:4889)
The score is driven primarily by persistent operating losses, negative cash flow, and weak technical momentum. The debt-free balance sheet offers some financial protection, but negative earnings and the absence of dividend support keep the overall profile highly speculative.
Renascience Inc. (4889) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 12.34B
- Dividend Yield
- ―
- Average Volume (3M)
- 259.93K
- Price to Earnings (P/E)
- -39.5
- Beta (1Y)
- 1.13
- Revenue Growth
- -21.15%
- EPS Growth
- -931.83%
- Country
- Japan
- Employees
- 3
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Pharmaceuticals
Renascience Inc. Business Overview & Revenue Model
Company Description
Renascience Inc., established in 2000 and based in Tokyo, Japan, is actively engaged in pioneering and bringing to market pharmaceuticals and medical devices throughout Japan. The company's pipeline includes RS5614, a PAI-1 inhibitor that has reached...
Renascience Inc. Financial Statement Overview
Summary
Financial performance is weak overall: the income statement and cash flow scores are very low because of large operating losses and persistent cash burn. A debt-free balance sheet and growing equity provide some support, but the company remains dependent on external funding.
Income Statement
32NegativeBalance Sheet
58NeutralCash Flow
30Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 68.55M | 68.55M | 132.69M | 194.16M | 100.55M | 139.33M |
| Gross Profit | 64.21M | 64.21M | 128.95M | 165.64M | 100.30M | 77.60M |
| EBITDA | -335.12M | -356.88M | 143.82M | -250.50M | -332.49M | -244.65M |
| Net Income | -316.44M | -301.28M | 113.43M | -258.33M | -335.80M | -254.29M |
Balance Sheet | ||||||
| Total Assets | 3.29B | 3.50B | 1.87B | 2.09B | 2.27B | 2.44B |
| Cash, Cash Equivalents and Short-Term Investments | 3.20B | 3.40B | 1.80B | 2.03B | 2.21B | 2.39B |
| Total Debt | 0 | 0 | 0 | 356.10M | 309.60M | 199.23M |
| Total Liabilities | 53.15M | 180.59M | 151.21M | 482.11M | 409.76M | 237.17M |
| Stockholders Equity | 3.24B | 3.32B | 1.72B | 1.61B | 1.87B | 2.20B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -291.31M | -177.14M | -232.10M | -286.87M | -231.66M |
| Operating Cash Flow | 0 | -291.31M | -176.34M | -230.52M | -284.64M | -230.49M |
| Investing Cash Flow | 0 | 0 | 382.15M | -1.57M | 232.00K | -296.00K |
| Financing Cash Flow | 0 | 1.89B | -52.18M | 46.50M | 110.37M | 1.59B |
Renascience Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4889, the sentiment is Negative. The current price of 896.00 is below the 20-day moving average (MA) of 945.15, below the 50-day MA of 1063.70, and below the 200-day MA of 1434.92, indicating a bearish trend. The MACD of -60.20 indicates Negative momentum. The RSI at 39.90 is Neutral, neither overbought nor oversold. The STOCH value of 59.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4889.
Renascience Inc. Peers Comparison
Overall Rating
JP:497844Neutral
JP:777442Neutral
JP:488939Underperform
JP:459339Underperform
JP:459938Underperform
JP:777637Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 44Neutral | JPY 11.65B | -25.06 | ― | ― | -8.23% | -48.10% | |
| 42Neutral | JPY 26.52B | -73.78 | ― | ― | 17.05% | 10.47% | |
| 39Underperform | JPY 12.34B | -39.45 | ― | ― | -21.15% | -931.83% | |
| 39Underperform | JPY 30.90B | -13.76 | ― | ― | -51.55% | 52.19% | |
| 38Underperform | JPY 7.33B | -3.94 | ― | ― | ― | 4.85% | |
| 37Underperform | JPY 6.70B | -5.83 | ― | ― | -49.43% | -3.77% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4889 | Renascience Inc. | 896.00 | -994.00 | -52.59% | |
| JP:4593 | Healios KK | 228.00 | -223.00 | -49.45% | |
| JP:4599 | StemRIM Inc. | 117.00 | -161.00 | -57.91% | |
| JP:4978 | ReproCELL Inc. | 109.00 | -48.00 | -30.57% | |
| JP:7774 | Japan Tissue Engineering Co., Ltd. | 653.00 | 175.00 | 36.61% | |
| JP:7776 | CellSeed Inc. | 169.00 | -232.00 | -57.86% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 06, 2026
